Future Pulse Cardiology

We would love to hear your thoughts on the episodes! Dr. Nero speaks with Dr. Greg Katz of NYU about the neutral topline results of the Lp(a) HORIZON trial and their implications for patient care. Beyond the trial readout, they explore how these findings reshape expectations that lowering Lp(a) will improve cardiovascular outcomes—and how to counsel and treat patients amid this uncertainty. They discuss current strategies, potential alternatives, and emerging therapies that may provide new an...

We would love to hear your thoughts on the episodes! Dr Thomas Nero discusses the new aldosterone synthase inhibitor Lorundrostat with Dr Liffert Vogt and the outcomes from the Launch HTN trial.

We would love to hear your thoughts on the episodes! Dr Thomas Nero discusses inflammation and the role of rheumatologic disorders on coronary artery disease with Dr Nehal Mehta, exploring how chronic inflammation serves as a cornerstone for various health issues, particularly in patients with conditions like psoriasis and serves as a model for investigating cardiovascular therapies. The discussion highlights the role of immune responses, the impact of lifestyle factors, and the importance of...

We would love to hear your thoughts on the episodes! Prof. Stefan Neubauer and Dr. Thomas Nero discuss two recent papers on the utility of coronary inflammation imaging on CT coronary angiography with Fat Attenuation Index (FAI)FAI score. The ORFAN study demonstrated a 20 fold increased risk in CV event rates with low vs high FAI score and a 10 fold increased event rate in patients with elevated FAI score who have no coronary plaque. FAI score re-categorized 40% of patients in their fol...

We would love to hear your thoughts on the episodes! Dr Gibson and Dr Nero discuss the oft maligned issue of medical statistics. Their discussion covers the pros and cons of traditional Cox proportional hazards regression models and Kaplan-Meier curves and newer techniques including win ratios. They then dip their toes into AI. A great overview by one of our leading clinical trialists.